The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The real-word evidence of first-line treatment of pembrolizumab in advanced NSCLC.
 
Pin Li
No Relationships to Disclose
 
Shirish M. Gadgeel
Honoraria - AstraZeneca; Genentech/Roche; Merck
Consulting or Advisory Role - AstraZeneca; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Daichii-Sanyko; Eisai; Genentech/Roche; Janssen Oncology; Jazz Pharmaceuticals; Lilly; Novartis; Novocure; Pfizer; Puma Biotechnology; Takeda; Xcovery
Research Funding - Amgen (Inst); ARIAD/Takeda (Inst); Astellas Pharma (Inst); AstraZeneca; AstraZeneca (Inst); Blueprint Medicines (Inst); Daiichi Sankyo (Inst); Genentech/Roche (Inst); I-Mab (Inst); Lycera (Inst); Merck; Merck (Inst); Nektar (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Genentech/Roche; Merck
Other Relationship - AstraZeneca
 
Laila Poisson
No Relationships to Disclose